Tammy Havener

Jan 22, 2025 | dx.doi.org | Sophia M. Min |Frances M. Bashore |Jeffery Smith |Tammy Havener

IntroductionClick to copy section linkSection link copied!Interest in inhibition of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as a therapeutic strategy has remained high since the seminal publication on apilimod, which touted it as a treatment for B-cell non-Hodgkin lymphoma. (1) Apilimod (Figure 1) has since been used as an exquisitely selective tool to interrogate PIKfyve biology in vitro and in vivo.